BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced updated results from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389).

Mythic Therapeutics today announced preclinical data highlighting the potential of MYTX-011, its investigational cMET-targeting ADC, for treating a broader range of cMET+ cancers than other cMET-targeting ADCs in development.

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in endometrial, ovarian, and cervical cancer cell lines.

Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts.

As Ghana becomes the first country in Africa and globally to approve the University of Oxford’s new malaria vaccine for young children, AIDS Healthcare Foundation (AHF) commends Ghana for its decision and urges the World Health Organization (WHO) to approve the vaccine quickly if current late-stage trials are successful.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens.

Arbutus Biopharma Corporation announced that two abstracts have been accepted as late-breaker oral presentations at the Global Hepatitis Summit 2023 taking place April 25-28, 2023, in Paris.

Chimerix announced a summary of presentations at the American Association for Cancer Research Annual Meeting, taking place April 14-19, 2023 in Orlando, FL.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended March 31, 2023.

Minerva Surgical, Inc., a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023.